Shafer and colleagues have found that human lysosomal cathepsin G is particularly antimicrobial against volutionary diverse pathogens such as Capnocytophaga sputigena, Escherichia coli, Neisseri gonorrhoeae, Pseudomonas aeruginosa, and Staphylococcus aureus. These investigators have studied the structure-function relationship of cathepsin G through the use of synthetic peptides that span the entire protein and have found that this protein has multiple antimicrobial domains that display """"""""target-specific"""""""" killing activity. However, one of these peptides, spanning residues 117-136 (CG 117-136) in the full-length protein, display the broad-spectrum antibacterial characteristic of the intact cathepsin G protein. Therefore, its activity may reflect the bactericidal capacity of the full-length protein. It is most active against S. aureus, a pathogen that often displays resistance to multiple antibiotics. This group has shown that the capacity of CG 117-136 to exert antibacterial action is independent of stereochemistry at the a carbon, suggesting that killing does not require recognition of a target with a chiral center but rather is mediated by a membrane-damaging mechanism. Shafer and colleagues now seek to ascertain the mechanism by which peptide CG 117-136 exerts broad-spectrum antimicrobial action in vitro. Using peptide synthesis procedures, these investigators will chemically modify CG 117-136 in order to identify regions essential for antimicrobial action (AIM 1). They will increase the cationic or hydrophobic properties of CG 117-136, which should enhance its capacity to interact with negatively charged microbial surface structures or promote insertion into the cytoplasmic membrane. Specifically chemical modifications will include substitution of neutral amino acids with arginine, extending the peptide with additional arginine groups, exchanging certain amino acids with more nonpolar residues, and attaching isoprenoid or fatty acid moieties to the peptide backbone. With such peptide variants Shafer and colleagues will conduct genetic and molecular experiments to help determine its mechanism of killing (AIM 2). Specifically, they will utilize Tn551 mutagenesis to identify mutants that express enhanced resistance to CG 117-136. Finally, using a rat infection model, this group will examine the capacity of CG 117-136 to exert antibacterial action in vivo and to reduce the incidence of abscesses in infected wounds (AIM 3). It is anticipated that these studies will help in the design and testing of new antimicrobial agents that can be used in the treatment of infections, particularly in those individuals with impaired host defenses or when the infecting pathogen display resistance to clinically useful antibiotics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI043316-02
Application #
2887772
Study Section
Special Emphasis Panel (ZRG5-BM-2 (03))
Program Officer
Heyse, Stephen P
Project Start
1998-07-15
Project End
2002-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Emory University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Duval, Brea D; Mathew, Anselmo; Satola, Sarah W et al. (2010) Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB. Antimicrob Agents Chemother 54:2283-90
Katzif, Samuel; Lee, Eun-Hee; Law, Anthony B et al. (2005) CspA regulates pigment production in Staphylococcus aureus through a SigB-dependent mechanism. J Bacteriol 187:8181-4
Zughaier, Susu M; Shafer, William M; Stephens, David S (2005) Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol 7:1251-62
Rivera-Marrero, Carlos A; Stewart, Julie; Shafer, William M et al. (2004) The down-regulation of cathepsin G in THP-1 monocytes after infection with Mycobacterium tuberculosis is associated with increased intracellular survival of bacilli. Infect Immun 72:5712-21
Sieprawska-Lupa, Magdalena; Mydel, Piotr; Krawczyk, Katarzyna et al. (2004) Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 48:4673-9
Katzif, Samuel; Danavall, Damien; Bowers, Samera et al. (2003) The major cold shock gene, cspA, is involved in the susceptibility of Staphylococcus aureus to an antimicrobial peptide of human cathepsin G. Infect Immun 71:4304-12
Mak, Pawel; Pohl, Jan; Dubin, Adam et al. (2003) The increased bactericidal activity of a fatty acid-modified synthetic antimicrobial peptide of human cathepsin G correlates with its enhanced capacity to interact with model membranes. Int J Antimicrob Agents 21:13-9
Shafer, W M; Katzif, S; Bowers, S et al. (2002) Tailoring an antibacterial peptide of human lysosomal cathepsin G to enhance its broad-spectrum action against antibiotic-resistant bacterial pathogens. Curr Pharm Des 8:695-702
Fallon, M T; Shafer, W; Jacob, E (1999) Use of cefazolin microspheres to treat localized methicillin-resistant Staphylococcus aureus infections in rats. J Surg Res 86:97-102